Skip to main content
SpringerLink
Log in

Systemischer Lupus Erythematodes (SLE)

  • Original Article
  • Published:
Wiener klinische Wochenschrift Education

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Hunnangkul S, Nitsch D, Rhodes B, Chadha S, Roberton CA, Pessoa-Lopes P, et al (2008) Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus. Arthritis Rheum 58: 1116–1124

    Article  PubMed  Google Scholar 

  • Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al (2010) Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16: 47–57

    Article  CAS  PubMed  Google Scholar 

  • Hahn BH, Ebling F, Singh RR, Singh RP, Karpouzas G, La Cava A (2005) Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 1051: 433–441

    Article  CAS  PubMed  Google Scholar 

  • Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349: 1526–1533

    Article  CAS  PubMed  Google Scholar 

  • Munoz LE, Janko C, Grossmayer GE, Frey B, Voll RE, Kern P, et al (2009) Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 60: 1733–1742

    Article  CAS  PubMed  Google Scholar 

  • Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61: 1168–1178

    Article  CAS  PubMed  Google Scholar 

  • Bonelli M, Smolen JS, Scheinecker C (2010) Treg and lupus. Ann Rheum Dis 69 [Suppl 1]: i65–66

    Article  CAS  PubMed  Google Scholar 

  • Klinman DM, Steinberg AD (1995) Inquiry into murine and human lupus. Immunol Rev 144: 157–193

    Article  CAS  PubMed  Google Scholar 

  • Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al (2005) Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 175: 8392–8400

    CAS  PubMed  Google Scholar 

  • Toussirot E, Roudier J (2008) Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 22: 883–896

    Article  CAS  PubMed  Google Scholar 

  • Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271–1277

    Article  CAS  PubMed  Google Scholar 

  • McKinley PS, Ouellette SC, Winkel GH (1995) The contributions of disease activity, sleep patterns, and depression to fatigue in systemic lupus erythematosus. A proposed model. Arthritis Rheum 38: 826–834

    Article  CAS  PubMed  Google Scholar 

  • Santiago MB, Galvao V (2008) Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature. Medicine (Baltimore) 87: 37–44

    Article  Google Scholar 

  • Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15: 241–250

    Article  PubMed  Google Scholar 

  • The Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324: 150–154

    Article  Google Scholar 

  • Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62: 863–868

    Article  PubMed  Google Scholar 

  • Wilson K, Abeles M (1994) A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 21: 1674–1677

    CAS  PubMed  Google Scholar 

  • Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65: 417–418

    Article  PubMed  Google Scholar 

  • Grossman JM (2009) Lupus arthritis. Best Pract Res Clin Rheumatol 23: 495–506

    Article  PubMed  Google Scholar 

  • Barile L, Lavalle C (1992) Transverse myelitis in systemic lupus erythematosus – the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol 19: 370–372

    CAS  PubMed  Google Scholar 

  • Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121–2131

    Article  CAS  PubMed  Google Scholar 

  • Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971–980

    Article  CAS  PubMed  Google Scholar 

  • Looney RJ, Anolik J, Sanz I (2010) A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 20: 1–10

    Article  PubMed  Google Scholar 

  • Looney RJ (2010) B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 70: 529–540

    Article  CAS  PubMed  Google Scholar 

  • Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62: 542–552

    Article  PubMed  Google Scholar 

  • Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal LH, Becker JC, Kelly S, et al (2009) Activity of Abatacept in SLE: Results of a 12-month phase II exploratory study. Annual European Congress of Rheumatology (EULAR), 2009

  • Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS, et al (2007) Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 56: 274–279

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinische Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Austria

    Michael Bonelli & Clemens Scheinecker

Authors
  1. Michael Bonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clemens Scheinecker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Bonelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonelli, M., Scheinecker, C. Systemischer Lupus Erythematodes (SLE). Wiener Klin. Wochenschr. Educ. 5, 31–47 (2010). https://doi.org/10.1007/s11812-010-0068-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11812-010-0068-2

Search

Navigation